In gastrointestinal stromal tumor (GIST), response to treatment is assessed by diagnostic imaging techniques, which is associated with limited sensitivity and specificity. There is no blood biomarker available to detect success or failure of therapy. In GIST, activating CKIT or PDGFRA mutations can be detect by DNA sequencing in tumor specimens in 90 per cent of the cases. Mutated genomic DNA fragments are highly specific for the tumor. We here show that tumor-specific mutations in CKIT or PDGFRA can be detected and quantified in free circulating DNA (fcDNA) in plasma samples derived from patients with GIST by quantitative ligation PCR, and that fcDNA levels correlate with the clinical course of the GIST lesions as measured by diagnostic imaging. Thus, tumor specific fcDNA in plasma can be used as highly specific biomarker in patients with GIST, and might be used to predict response to treatment and relapse, allowing earlier treatment changes. 
Introduction
In GIST, the main objective of treatment is complete resection. Tyrosine kinase inhibitors like imatinib or sunitinib are used for neoadjuvant, adjuvant or palliative treatment. Responses to imatinib can be achieved. However, treatment is not curative unless complete resection is possible. In advanced GIST, a partial remission can be attained in 50 per cent of patients treated with imatinib, and there are single cases of complete responses. However, most patients experience disease progression receiving imatinib (1) (2) (3) (4) (5) (6) (7) . Patients with progression receiving imatinib only transiently respond to sunitinib (8) .
The response to therapy is evaluated by diagnostic imaging, which displays limited sensitivity and specificity. Computed tomography (CT) constitutes the gold standard of imaging in GIST (9, 10) . However, sensitivity of CT in GIST is insufficient. A randomized trial investigating the interruption of imatinib in patients with advanced GIST was terminated prematurely due to a high rate of progression events in the interruption arm even in patients displaying CT-morphologic complete remission at the time of randomization (11). Currently, [18F]-2,-Fluoro-2,-desoxy-D-Glukose positron emission-tomography (FDG-PET) represents the most sensitive imaging technique for staging and monitoring response in GIST. However, the sensitivity and specificity of FDG-PET in GIST is limited (12) (13) (14) . In a recent study the sensitivity and specificity of FDG-PET/CT for detecting intraoperatively occult metastases in patients with GIST and R0 resection was 25% and 88%, respectively (15) . Even in cases with FDG-PET/CT complete response, lesions contained viable tumor (16) .
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Activating mutations of the stem cell factor receptor tyrosine kinase (CKIT) or the platelet-derived growth factor receptor alpha (PDGFRA) can be found in at least 85% of all cases in gastrointestinal stroma tumor (GIST) and constitute the transforming event in the pathogenesis of GIST tumors (17) (18) (19) (20) (21) .
Free circulating DNA can be detected in normal individuals but however, is increased in tumor patients (22) (23) (24) (25) . Proposed models for tumor-DNA release into the blood include DNA release by tumor cells that undergo apoptosis or necrosis, and extravasation of tumor cells into the blood where cells undergo lysis and release their DNA content into the blood (26). It has been shown that levels of LINE1 DNA in plasma samples correlate with tumor progression in different cancer entities (27) (28) (29) (30) but, however LINE1 sequences are not tumor specific.
Recently it was demonstrated that EGFR mutations can be recovered in free circulating (fc)DNA in serum samples of patients with non-small cell lung cancer (31) , and detection of circulating mutant APC, p53 or KRAS DNA was shown to correlate with progression-free survival in patients with colorectal cancer (32) .
A sensitive, non-invasive biomarker for detection and quantitation of disease activity would be a highly valuable tool for the management of GIST. Genomic tumor DNA from the resection specimen can be used to identify the patient specific CKIT or PDGFRA mutation present in GIST tumor cells. In this trial, we aimed to evaluate whether tumor DNA carrying mutations for CKIT and PDGFRA can be detected and quantified in the plasma of patients with GIST, and whether detection can be correlated with the clinical course of disease and results of diagnostic imaging studies.
Research. Using allele-specific Ligation PCR, we were for the first time able to detect fragments of genomic DNA containing the tumor-specific mutation in plasma samples derived from GIST patients, and our data suggest that non invasive detection of tumor derived fcDNA measured in plasma samples correlates with disease activity.
Materials and methods
Trial design. This study is an open-label, non-randomized, non interventional, explorative phase IIIb trial that aims to detect tumor specific mutations of CKIT or Patients. The 38 cases included 18 patients with active disease, which was defined as having at least one GIST lesion that could be measured by imaging at any time after inclusion. Of these, nine displayed active disease before TKI treatment was instituted (first diagnosis, n=2; relapse, n=5; after surgical debulking, n=2) and nine patients had relapse or progression receiving TKI treatment, including three patients with response to TKI treatment where no samples were available at progression before TKI. Twenty patients were in complete remission but with high (n=14), moderate (n=3) or low (n=1) risk of relapse according to Miettinen criteria (43), or were in CR and Miettinen criteria were not applicable because mitotic index was not available (n=1) or treated local peritoneal metastasis (n=1) (see Table 1 Sequence analysis of CKIT exons 9, 11, 13, 14, 17, 18 and PDGFRA exon 18 was performed on a routine basis. Furthermore, in all cases were tumor specimens were available (30/38 cases; 79%), we repeated sanger sequencing for confirmation of the initial mutation status.
Isolation of tumor DNA from plasma. Peripheral blood samples were collected into EDTA tubes (Sarstedt). At the same day, tubes were centrifuged at 800g for 10 min.
The supernatant was transferred to 10-ml tubes and centrifuged at 1.600g for 10 min to remove debris. Plasma supernatants were transferred in 1.0 ml aliquots to 1. Statistical analyses. Statistical analysis was performed using Student's unpaired t-test with 95% confidence intervals.
All authors had access to the study data and have reviewed and approved the final manuscript.
Results

Validation of allele-specific Ligation PCR application
The application of the Ligation PCR showed in a total of 25 assays an interassay coefficient of variation (standard deviation/mean) of 0.2 to 0.5, investigated in five independent runs performed on different days and calculated from five log10 dilutions between 10^4 to 10^8 CKIT exon 9 insertion 502-503 mutated copies in duplicates.
The intraassay coefficients of variations were 0.4 to 0.5 calculated from the means of eight replicates of plasmid dilutions of CKIT exon 9 insertion 502-503 between 10^4 to 10^7 copies. Sensitivity has been tested for 6 cloned key mutations (CKIT exon 9 insertion 502-503; CKIT exon 11 deletion 557-558; CKIT exon 11 V559D; PDGFRA exon 18 D842V; CKIT exon 13 V654A; CKIT exon 13 K642E) and ranged from 0.01% to 0.1% mutated allele/wild type dependent on cross reactivity of hybridizing probes. This results in a dynamic detection range of 4-5 log10. One exception was K642E with a higher cross reactivity of 1% and a subsequent detection range of 3 log10. (Figure 2 ). Eighteen out of 38 patients had active disease, which was defined as having at least one lesion that could be measured at any time after inclusion and being either before institution of TKI treatment (n=9) or with relapse or progression receiving TKI treatment (n=9; Tables 1, 2 ). In nine of these 18 patients, we detected fcDNA harbouring the tumor-specific mutation, with mutant to wild-type allele ratios of >0.1% (up to 15.6%) in five cases and less than 0.1% in four cases (Table 1) . We identified mutant fcDNA in four out of six patients with progression or relapse receiving TKI (patients 5, 7, 11 and 15; Table 2, Figure 2 , suppl. Table S2 ). We did not detect mutant fcDNA in three patients that were already responding to TKI treatment at the time of the first plasma sample (patients 2, 4 and 9). In contrast to patients with active disease, none of the patients in CR displayed mutant to wt allele ratios above 0.1%, but we were still able to detect low levels of mutant fcDNA (less than 0.1%) in six out of 17 patients with high or intermediate risk of relapse according to Miettinen (Table 1) . When we analysed "untreated and progression" versus "CR" patients with positive test results, the former category displayed significantly higher fcDNA ratios (Figure 1) 
Detection of tumor-specific
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Quantification of tumor derived plasma DNA and correlation with radiographic response to treatment
We next examined whether the amount of tumor fcDNA correlated with response.
The clinical characteristics and treatments for all 38 patients are shown in Table 3 . In five of 18 patients with active disease we found fcDNA harbouring the tumor-specific mutation, with mutant to wild-type allele ratios of >0.1% (Table 1, Figure 3A -E). We observed repeated positive test results in patients with progression (patients 5, 11, 15) or relapse (patients 7, 10; see Figure 2 ). In patients 7 and 10, tumor relapse was paralleled by a negative to positive conversion.
Mutated fcDNA test result of patient 5 shortly after surgery on day 0 (0.04%) was low level positive with the tumor specific CKIT exon 9 insertion AY502-503 mutation Patient 8 was diagnosed with cardiac GIST and liver metastasis with a CKIT exon 11 K550-K558 deletion. We observed a positive to negative conversion from 14.1% to 0% mutant plasma fcDNA after only 14 days of treatment with imatinib ( Figure 3D ).
Of note, CT scans starting from day 94 showed an ongoing response of liver lesions (red arrows) with persistently negative tumor fcDNA with a follow up of 29 months and a corresponding steady decline of LINE1 DNA fragments over time.
In accordance with the rapid positive to negative conversion seen in patients 7 and 8, we did not detect fcDNA in plasma samples from three additional patients that responded to TKI treatment where pre-treatment samples were not available (see Table 2 , category "With response receiving TKI"; patients 2, 4 and 9 in Table 2 ). In two patients sequentially performed molecular analyses of surgically debulked peritoneal tumor revealed secondary resistance mutations in addition to the primary mutation (CKIT exon 13 V654A in patient 11, Figure 3E ; CKIT exon 17 D820Y in patient 10, Figure 3C ). Both additional mutations are known to confer imatinib resistance (35) . Of note, we were able to detect these additional mutations also in subsequent plasma samples. In patient 10, earlier plasma samples were available and interestingly, we were able to track back the exon 17 D820Y mutation to three out of seven earlier samples taken up to two years before this mutation was found in the tumor specimen. Patient 11 had stable metastases in the liver and rapidly progressing mesenteric metastases ( Figure 3E , red arrows). In plasma samples of this patient, fcDNA containing the initial mutation (CKIT exon 11 V559D) decreased in despite of rapid progression ( Figure 3E ). In parallel, a secondary CKIT exon 13 V654A mutation identified from a mesenteric lesion after debulking on day 0 ( Figure 3E , black arrow) emerged in fcDNA during progression on day 328 together with a steady increase of LINE1 DNA fragments over time. We therefore suspected polyclonal disease and suspected additional secondary mutations. Indeed, were able to detect CKIT exon 9 insertion AY502-503 in four samples (0.01-0.05%), and exon 13 K642E in two samples (0.11-0.24%; data not shown). In this study, we could demonstrate that mutant fcDNA specifically can be detected and quantified in the plasma of patients with GIST. Our data indicate that the amount of mutant fcDNA correlates with response. We observed repeatedly positive results and increasing mutant fcDNA in patients with progression, negative to positive conversions in patients with relapse, and positive to negative conversions in patients responding to TKI treatment.
Our finding of very rapid (within two weeks) and durable positive to negative conversion in two patients responding, and a negative to positive conversion preceding radiographic relapse by three months suggest that detection of fcDNA might be used as tumor-specific biomarker to predict response early after initiation of treatment, and to predict relapse. We were able to detect mutant fcDNA in nine out of these 18 cases with active disease. There are several possible explanations for the negative cases. First, three negative cases fulfilled the pre-specified criteria for active disease (at least one lesion that could be measured) but however no samples were available at the time of progression, and samples at the time of response to TKI were negative ( Table 2 ). In addition, biologic properties inherent to the tumor such as vascularisation, cell turn over, apoptosis rate, active secretion of DNA and/or RNA and localization might impact the release of nucleic acids into the blood stream (26, 38). Furthermore, 3/9 negative patients with active disease carried large duplications that can hamper detection caused by ineffective probe hybridisation (43-57 base pairs, patient 2, 4 and 14, suppl. Table S1 ). Sensitivities of our assays ranged between 0.01% to 0.1% mutation/wild type allele. The K642E assay was an exception with 
0.8% cross reactivity reducing the sensitivity to 1%, due to a high GC content of the hybridization probe. More sensitive mutation detection assays might reduce false negative results. In addition, polyclonal disease and clonal competition may hamper the detection of individual mutations in plasma, especially when clones become dominant that do not harbour the initial mutation. Imatinib resistance in GIST lesions is associated with acquisition of secondary CKIT or PDGFRA mutations that mediate inhibitor resistance (40) (41) (42) . Importantly, specific lesions may carry different mutations, indicating polyclonal resistance (40, 42) . However, repeated biopsies of different lesions are not feasible. In two patients, we were able to separately track back and forth distinct clones harbouring individual mutations, including mutations not known from biopsies, indicating clonal heterogeneity and competition during treatment. In the future alternative technologies such as targeted massive parallel sequencing or multiplex assays might simultaneously identify and quantitate secondary disease subclones allowing unbiased detection of sequence changes and thus might mirror clonal heterogeneity. This includes secondary mutations mediating resistance to treatment, allowing earlier treatment changes without repeated tumor biopsies. We are currently expanding our analysis of secondary resistance mutations in plasma samples of patients with progressive disease and low or decreasing amounts of the initial mutation.
In six out of 20 patients in complete remission, we were able to detect mutant fcDNA in plasma at low levels, indicating that viable tumor remains in a proportion of patients after removal of the primary. We were not able to establish a correlation of Miettinen risk to fcDNA positivity due to low number of patients, and possibly also due to the fact that all high risk patients received adjuvant imatinib. However, with longer follow up it will be important to correlate test positivity with relapse especially a Includes 3 cases with samples available at the time of response only (see Table 2 ) 
